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Abstract: 
Status epilepticus (SE) is one of the most frequent neurological emergencies, and a rapid 
and effective treatment is warranted. Current guidelines recommend a step-wise approach 
using a sequence of different anti-epileptic drugs (AED) with be benzodiazepines (BZD) 
being the first treatment proposed. In order to provide a more effective treatment as soon as 
possible, some authors have suggested using a combined polytherapy as first line treatment. 
Strong evidences support the use of BZD, mostly lorazepam and midazolam as initial 
monotherapy treatment for SE. Insufficient data are available to support the use of non-
sedating AED as phenytoin, valproic acid or levetiracetam without a previous BZD 
administration. Studies assessing the role of a combined initial therapy are rare, if not 
missing. Moreover, due to the wide range of SE etiologies a “one fits all” initial polytherapy 
seems difficult to achieve. After reviewing the available evidences, guidelines and current 
practices regarding mono- and polytherapy as first line treatment in SE in adults, we propose 
a rational algorithm for early anti-seizure treatment in SE.  
  
1. Introduction: 
Status epilepticus (SE) is one of the most frequent neurological emergencies and is 
associated high mortality ranging from 3-33% (Koubeissi and Alshekhlee, 2007), (Knake et 
al., 2001), (Vignatelli et al., 2003); therefore, a rapid and effective treatment is recommended 
(Brophy et al., 2012), (Meierkord et al., 2010). Current American (Brophy et al., 2012) and 
European (Meierkord et al., 2010) guidelines suggest a step-wise approach using a 
sequence of different anti-epileptic drugs (AED). The first recommended line of treatment is 
an intravenous (iv) benzodiazepine (BZD), based on class I evidence (Leppik et al., 1983), 
(Treiman et al., 1998), (Alldredge et al., 2001), (Silbergleit et al., 2012). In case of ongoing 
seizures, a second line of AED is proposed. However in order to provide a more rapid and 
incisive treatment some authors have proposed to use a combined polytherapy as first line, 
by merging the first and second line (Millikan et al., 2009), (Navarro et al., 2011).  
The aim of this article is to review the available data and current practice regarding the early 
anti-seizure medication in SE and to clarify if there is enough evidence supporting rather a 
mono- or a combined polytherapy approach for the initial anti-seizure treatment in SE 
management in adults. 
 
2. Monotherapy for first-line treatment: existing evidence 
2.1 Benzodiazepines: 
Several randomized-control studies showing the efficacy of BZD as first line therapy have 
been published. The first one was performed in the early eighties (Leppik et al., 1983); a total 
of 70 adult patients with all type of SE were randomized between iv lorazepam (LZP) 4 mg or 
iv diazepam (DZP) 10 mg. LZP controlled the seizures in 89% of cases, and DZP in 76%; 
this difference didn’t reach a statistical significance. The Veteran Affairs (VA) cooperative 
study (Treiman et al., 1998), performed the following decade, was a double-blind trial 
conducted in 16 centers in the US, and randomized 384 patients with generalized convulsive 
SE into four arms: iv LZP 0.1 mg/kg, iv phenobarbital (PB) 15 mg/kg, iv DZP 0.15 mg/kg 
associated with iv phenytoin (PHT) 18 mg/kg, or iv PHT 18 mg/kg alone. LZP was the most 
efficient to stop the seizure with 64.9% of success; this was statistically better than PHT 
alone.  A third study randomized in a pre-hospital setting 205 patients with general 
convulsive SE between iv LZP 2 mg, iv DZP 5 mg and placebo (Alldredge et al., 2001). Only 
21.1% of the SE episodes were controlled by placebo, while DZP and LZP stopped the 
seizures in 42.6% and 59.1% of cases, respectively; here again there was no statistical 
difference among the benzodiazepines, while both agents were better than placebo. The 
RAMPART study is the most recent trial (Silbergleit et al., 2012), where 893 adult and 
pediatric patients with generalized convulsive SE were randomized to iv LZP 4 mg and 
intramuscular (im) midazolam (MDZ) 10 mg for emergent pre-hospital treatment, and 
designed as a non-inferiority trial. There was a trend in favor of im MDZ over iv LZP for early 
seizure control (73.4% vs. 63.4%); this difference is likely explained by the speed and 
easiness of administration rather than the drug itself. Indeed, in that trial the im route was 
clearly faster than the iv one.  
Finally, it is also important to mention that iv clonazepam (CLZ) 0.015 mg/kg, which is 
registered and used in many European and South-American countries to treat SE (Shorvon 
et al., 2008) has been far less extensively studied than the aforementioned compounds. A 
trial performed in 61 patients with severe refractory epilepsy and repeated episodes of SE 
found that the CLZ efficacy was comparable to LZP (Sorel et al., 1981), and an open study 
reported CLZ to be rapidly effective and safe in SE management with a mean time to seizure 
control of 1.75 min (Singh and Le Morvan, 1982). More recently a observational study of 177 




2.2 Non-sedating AED 
Non-sedating AEDs have also been studied as first line agent. A trial performed in India, 
assessed the efficacy of valproic acid (VPA) 30 mg/kg and PHT 18mg/kg as first line 
treatment by randomizing 68 patients with convulsive SE (Misra et al., 2006). VPA aborted 
the seizures in two third of patients, while PHT only in 42%, suggesting that VPA may be 
more effective. This study was however underpowered to draw definitive conclusions. Similar 
results were found in a prospective open-label assessment of 74 patients suffering from a SE 
or acute repetitive seizures (Gilad et al., 2008). A rescue medication was needed for 12.3% 
of patients in the VPA group and 12% in the PHT group. Levetiracetam (LEV) has also been 
studied in this setting; this has been recently summarized (Shin and Davis, 2013). There is 
however only one randomized study from India including 79 patients, showing that LEV 20 
mg/kg controls convulsive SE in three quarters of patients, a similar rate than LZP 0.1 mg/kg 
(Misra et al., 2012); slightly more patients were seizure free at 24 hours in the LEV group. 
Beside this single prospective study, some retrospective surveys with limited numbers of 
subjects reported favorable outcome for patients treated with LEV as a first line therapy in 
different population including 9 elderly patients (Fattouch et al., 2010), 2 subjects at high risk 
of respiratory distress (Berning et al., 2009) and 12 (Rüegg et al., 2008) and 17 critically ill 
patients (Nau et al., 2009).  
2.3 Conclusions 
While there are strong evidences to support the use of BZD as first line treatment, favoring 
among them the compound that may be administered most easily, evidences supporting the 




3. Polytherapy for first-line treatment: available evidences 
3.1 Existing evidence 
In general, well-conducted studies beyond the first treatment line are extremely scarce 
(Rossetti and Lowenstein, 2011), and the knowledge gap regarding a combined polytherapy 
approach is even bigger. The VA cooperative study (Treiman et al., 1998) included one arm 
of a combined treatment including DZP 0.15 mg/kg given together with PHT 18 mg/kg. This 
polytherapy group showed however a (non-significant) lower rate of seizure control than LZP 
or PB (55.8% vs. 64.9% and 64.2% respectively), while it was better than PHT alone. Of 
note, the primary outcome was seizure control 20 minutes after the start of drug infusion, and 
PTH was delivered at a maximal rate of 50mg/min; PHT infusion might therefore not have 
been completed at the time of the primary outcome assessment. There was no difference 
between the four groups regarding seizure recurrence rate at 24 hours and clinical outcome 
at 30 days.  
An ongoing study is assessing in France the question of combined early therapy by 
randomizing patients between CLZ 1mg + LEV 2500 mg iv versus CLZ 1mg + placebo 
(Navarro et al., 2011). Results have not been published yet, but this attempt may potentially 
provide very instructive results. Another French observational study focusing on pre-hospital 
management of convulsive status found a greater efficacy of the combination of a BZD (DZP 
10mg or CLZ 1mg) with a non-sedating AED (fosphenytoin 30 mg/kg or VPA 30mg/kg) than 
a BZD alone (Aranda et al., 2010). The drugs combination was effective in 70% of patients 
whereas BZD alone stopped the seizures in only 30% of cases. According to the authors of 
this study, their findings emphasize the need for early use of a long-acting agent other than 
BZD. 
3.2 Conclusion 
Immediate combined polytherapy for SE has not been studied sufficiently to recommend its 
use. There are however some clues that early combined treatment may be useful. 
 4. Current guidelines and practice for SE first line therapy 
4.1 Current guidelines 
Both the American (Brophy et al., 2012) and European (Meierkord et al., 2010) guidelines 
recommend a stepwise treatment. The US recommendation propose to change the 
traditional “1st, 2nd, 3rd,… line of treatment”, to “emergent initial therapy”, “urgent control 
therapy” and “refractory therapy”, which reflect more the need for urgent SE control (Brophy 
et al., 2012). BZD are recommended as “emergent initial therapy” for all patients. Because of 
the available evidence, LZP 0.1 mg/kg is recommended for iv, and MDZ 10 mg for im 
treatment. Then, an “urgent control therapy” is recommended for all patients, except when 
the definite underlying cause has been identified and successfully addressed, such as 
severe hypoglycemia for example. The second treatment aims to maintain seizure control 
when BZD were successful, or to stop seizures if the first line failed. The guideline states that 
there is a disagreement regarding the most effective drug in this setting, due to the lack of 
available evidence; iv PHT or fosPHT, VPA, LEV, PB or (even) MDZ in continuous infusion 
are however proposed for the second step of treatment. The “urgent control” therapy should 
rapidly follow the first line, but there is no mention of a combined initial treatment. The 
European guidelines published before the RAMPART study (Meierkord et al., 2010), 
recommend iv LZP as a first choice, or a combination of DZP 10 mg and PHT 18mg/kg, in 
line with the VA cooperation study (Treiman et al., 1998) if LZP is not available. 
4.2 Clinical practice 
In a SE management survey fifteen academic centers across the US were asked to 
retrospectively reported their practice on the 10 to 20 last patients treated for SE in their own 
institution (Cook et al., 2012). Three quarters of patients received a BZD (mainly LZP) as first 
line therapy, followed by PHT in 8.7% of patients. Of note, there is no mention of a combined 
first line therapy. Polytherapy used as initial therapy was not mentioned either in two SE 
management practice surveys based on hypothetical case (Claassen et al., 2003), (Riviello 
et al., 2013), but it is important to remind that the questions asked in the survey didn’t evoke 
any combined therapy. Finally, the rate of success of first line therapy in observational 
studies is lower than reported in controlled trials (Aranda et al., 2010), (Alvarez et al., 2011), 
(Cook et al., 2012), (Rantsch et al., 2013), probably reflecting the common practice of a rapid 
second line treatment administration without waiting for first line failure to control the 
seizures. 
 
5. Special considerations  
It is commonly agreed that SE requires a rapid and effective treatment. There are several 
class I studies pointing that BZD should be used initially; it seems also important to prevent 
seizures recurrence by administering a “second line” or “urgent control therapy” (Brophy et 
al., 2012). There are however not enough data to recommend a specific combined therapy in 
all patients. Moreover, some clinical situations require particular considerations.  
5.1 Specific clinical situations 
Alcohol withdrawal represents a frequent cause of SE (Aminoff and Simon, 1980), 
(DeLorenzo et al., 1996) and PHT is not effective in this setting (Kosten and O’Connor, 
2004). BZD treatment and thiamine administration are required (Mayo-Smith, 1997). VPA 
may reduce symptoms of alcohol withdrawal and thus could be considered additionally 
(Kosten and O’Connor, 2004). Also, BZD withdrawal can induce SE and, logically, its 
treatment requires a prolonged gradual weaning of a benzodiazepine with a long half-life 
(Leach et al., 2012) and not a non-sedating AED. The same considerations apply for SE due 
to severe disturbances of glycaemia (hyper- or hypo-): a tight glucose level control is 
required, rather than further AED (Beleza, 2012).  
PHT is one of the recommended (Brophy et al., 2012), (Meierkord et al., 2010) and, at least 
historically, the most widely used drug after BZD administration (Cook et al., 2012). However 
it may aggravate seizure in genetic generalized epilepsies (also known as idiopathic 
generalized epilepsies) with absence and myoclonic seizures (Benbadis et al., 2003) and 
even precipitate SE (Thomas et al., 2006). PHT should therefore not be used in this 
population, where VPA is the drug of choice after BZD administration (Wheless, 2003). LEV 
is also an effective treatment in genetic generalized epilepsies (Berkovic et al., 2007), but its 
role in SE in this population has not been studied. 
Finally PHT and VPA should be used with caution in patients with hepatic disease 
(Asconapé, 2014) or with premorbid polypharmacy (Asconapé, 2002), because of possible 
medical interactions. LEV or lacosamide (LCM) are however safe in patient with hepatic 
diseases, and are almost devoid of relevant pharmacokinetic interactions. 
 
6. Proposed approach and conclusion 
A “one fits all” solution applying for all SE patients does not exist, reflecting the marked 
heterogeneity in terms of etiologies, ages and medical comorbidities. The answer to the 
question proposed in the title is still open, if one considers evidence-based approaches. 
However, there is a clear evidence to recommend the use of BZD as an immediate 
treatment, and to suggest considering a second, non-sedating drug to maintain or achieve 
seizure control. Waiting for possible future evidence regarding initial combined polytherapy, 
we propose here an algorithm (Figure 1) of early seizure treatment in SE based on the 
above discussion.  
Well designed randomized studies are required to outline the better way to treat these 
patients in the early phase and some ongoing studies (Navarro et al., 2011), (Bleck et al., 
2013) will hopefully provide soon precious information in this sense.  
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Figure 1: Proposed rational algorithm for early seizure management in status epilepticus in adults 
 
Abbreviations:  
BZD: benzodiazepine; EtOH: alcohol; I/GGE: idiopathic / genetic generalized epilepsy; im: intra-muscular; iv: intravenous; LEV: levetiracetam; PHT: phenytoin; SE: status 
epilepticus; VPA: valproic acid 
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+""
iv"thiamine"if"EtOH"
Not"in"a"seIng"of"severe"glycemic"
disturbances"nor"EtOH"withdrawal"
No"history"of"
hepaLc"disease"
and"no"mulLple"
premorbid"drugs"
PHT/fPHT"20"mg/kg"iv"
or""
VPA"20R30"mg/kg"iv"
or"
LEV"20R30"mg/kg"iv"
"History"of"
HepaLc"disease"
LEV"20R30"mg/kg"
iv"
MulLple"
premorbid"
treatment""
(drug"interacLon)"
No"available"informaLon"
First"treatment"
Immediately"
Ra
pi
d"
cl
in
ic
al
"a
ss
es
sm
en
t/
Rapid"
second"
treatment"
History"of"I/GGE" De"novo""SE"or"history"of"
epilepsy"other"than"I/GGE"
VPA"20R30"mg/kg"iv"
Severe"glycemic"
disturbances"
Glucose"level"
control"
